Sound View Wealth Advisors Group LLC Decreases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Sound View Wealth Advisors Group LLC lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,691 shares of the medical research company’s stock after selling 336 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Edwards Lifesciences were worth $347,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter valued at about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the period. Finally, Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $46,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $68.49 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a 50-day simple moving average of $72.14 and a two-hundred day simple moving average of $70.37. The firm has a market capitalization of $40.26 billion, a PE ratio of 9.83, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of several research reports. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,303 shares of company stock valued at $3,255,356 over the last three months. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.